Recognition and Prevention of Inhalant Abuse
Am Fam Physician. 2003 Sep 1;68(5):869-874.
Inhalant abuse is a prevalent and often overlooked form of substance abuse in adolescents. Survey results consistently show that nearly 20 percent of children in middle school and high school have experimented with inhaled substances. The method of delivery is inhalation of a solvent from its container, a soaked rag, or a bag. Solvents include almost any household cleaning agent or propellant, paint thinner, glue, and lighter fluid. Inhalant abuse typically can cause a euphoric feeling and can become addictive. Acute effects include sudden sniffing death syndrome, asphyxia, and serious injuries (e.g., falls, burns, frostbite). Chronic inhalant abuse can damage cardiac, renal, hepatic, and neurologic systems. Inhalant abuse during pregnancy can cause fetal abnormalities. Diagnosis of inhalant abuse is difficult and relies almost entirely on a thorough history and a high index of suspicion. No specific laboratory tests confirm solvent inhalation. Treatment is generally supportive, because there are no reversal agents for inhalant intoxication. Education of young persons and their parents is essential to decrease experimentation with inhalants.
Although inhalant abuse is quite prevalent, it is an often overlooked form of substance abuse in adolescents. National surveys1 report that nearly 20 percent of young persons have experimented with inhalants at least once by the time they are in eighth grade. In the United States, the mean age of first-time inhalant abuse is 13 years.2 At present, rates of abuse are higher in Hispanics and whites than in blacks.
Because the inhalants that are abused are in common household products and are relatively inexpensive, they are accessible to children who are too poor or too young to access other drugs. Furthermore, inhalant abuse appears to be a gateway phenomenon among younger adolescents: children who abuse inhalants early in life are more likely later to use other illicit drugs.3,4
Injuries and illnesses related to inhalant abuse occur with alarming frequency. Hence, family physicians should be alert to the presence of this form of substance abuse in young patients and should provide information about its acute and chronic effects. Parents also should be educated about the warning signs and dangers of inhalant abuse.
Illustrative Case 1
A 21-year-old man is unconscious when he is brought to the emergency department. His friends report that he has been “huffing” (placing a rag soaked in a substance over his nose and mouth and then inhaling) for several months. On examination, the thin young man is briefly arousable to deep pain. He slowly becomes more arousable. Laboratory tests and a computed tomographic (CT) scan of the head are negative. At 24 hours after presentation, the patient becomes completely coherent and demands to be released from the hospital. He is released against medical advice.
Three weeks later, the young man again presents to the emergency department, this time in full cardiac arrest. After extensive resuscitative efforts, the patient dies. Family and friends confirm that he had been inhaling gun cleaner daily.
Illustrative Case 2
A 13-year-old girl with a primary complaint of headaches is brought to the physician's office by her mother. The patient reports headaches that have been increasing in frequency over the past year and are now present daily. The headaches have resulted in several days missed from school. The patient's mother also notes that the adolescent occasionally seems confused and uncoordinated (“clumsy”), and is “not eating much.” Her grades have declined dramatically over the past semester.
On physical examination, the patient is noted to have dry, cracked perioral skin with irritation and sores on the lips, and fingernail beds that appear to be stained with ink. The examination is otherwise normal. During private questioning, the patient admits to sniffing glue and spray paint “once or twice” with a friend over the past few months.
Inhalant abuse involves breathing in a substance directly from its container (sniffing or snorting), placing a rag soaked in the substance over the nose and mouth and inhaling (“huffing”), or pouring the substance into a plastic bag and breathing the fumes (“bagging”).5(pp257–60)
Abused substances include fuels, solvents, propellants, glues, adhesives, and paint thinners. The active chemicals in commonly abused inhalants are listed in Table 1.6,7 Abuse of amyl and butyl nitrites (called “poppers”) is not included in this review because of the different mechanism of action and adverse effects of these substances.8 Inhaled solvents likely share cellular actions with γ-aminobutyric acid–receptor drugs (e.g., benzodiazepines, barbiturates, alcohol), resulting in a depressant effect.5(pp257–60)
TABLE 1 Chemicals in Commonly Abused Inhalants
Chemicals in Commonly Abused Inhalants
|Chemical||Commonly abused inhalants|
Paint thinner, spray paint, airplane glue, rubber cement, nail polish remover, shoe polish
Lighter fluid, fuel, spray paint, hair spray, room freshener, deodorants
Gas grill fuel, spray paint, hair spray, room freshener, deodorants
Asthma sprays, analgesic sprays, Freon® gas, spray paint, hair spray, deodorants, room fresheners
Dry-cleaning agents, spot removers, degreasers, correction fluid
Nail polish remover, rubber cement, permanent markers
Adapted with permission from Bowen SE, Daniel J, Balster RL. Deaths associated with inhalant abuse in Virginia from 1987 to 1996. Drug Alcohol Depend 1999;53:241, and Sharp CW, Rosenberg NL. Inhalants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook. 3d ed. Baltimore: Williams & Wilkins, 1997:246–64.
Use of inhalants can produce a euphoric feeling similar to that experienced with other illicit drugs.9 When a person using inhalants becomes hypercapnic and hypoxic by rebreathing from a closed bag, the effects of the inhalant are intensified.8
TABLE 2 Diagnostic Criteria for Inhalant Intoxication
Diagnostic Criteria for Inhalant Intoxication
Recent intentional use or short-term, high-dose exposure to volatile inhalants (excluding anesthetic gases and short-acting vasodilators)
Clinically significant maladaptive behavior or psychologic changes (e.g., belligerence, assaultiveness, apathy, impaired judgment, impaired social or occupational functioning) that developed during, or shortly after, use of or exposure to volatile inhalants
Two (or more) of the following signs developing during, or shortly after, inhalant use or exposure: dizziness, nystagmus, incoordination, slurred speech, unsteady gait, lethargy, depressed reflexes, psychomotor retardation, tremor, generalized muscle weakness, blurred vision or diplopia, stupor or coma, or euphoria
The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder.
Adapted with permission from American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Rev. Washington, D.C.: American Psychiatric Association, 2000:239.
In the office setting, it is seldom obvious which preadolescent or adolescent patients are abusing inhalants. Victims of child abuse tend to be at greater risk for inhalant abuse,10 as are young persons whose friends or relatives abuse other substances.
Patients who have been abusing inhalants may report dizziness, irritability, tiredness, loss of appetite, headache, photophobia, or cough.11,12 Most symptoms are nonspecific and can be mistaken for those of other illnesses or syndromes. Signs of recent inhalant abuse include paint or oil stains on clothing or skin, spots or sores around the mouth, red eyes, rhinorrhea, chemical odor on the breath, and a dazed appearance (Table 3).13 Patients with long-term inhalant abuse can present to the emergency department or office setting with a wide range of neuropsychiatric signs and symptoms. The most commonly recognized acute presentation is sudden unconsciousness or death during known inhalation of a solvent. Other, nonspecific complaints include the following: memory loss, especially loss of short-term memory; delusions or hallucinations; slurred or changed speech; staggering, stumbling, or wide-based ataxic gait; visual and optical changes, such as nystagmus; and loss of hearing or sense of smell.8 Unfortunately, no specific syndromes or clinical presentations confirm inhalant abuse.
TABLE 3 Signs and Symptoms of Inhalant Abuse
Signs and Symptoms of Inhalant Abuse
Paint or oil stains on clothing or body Chemical odor on breath Spots or sores in or around mouth Rhinorrhea Injected sclera Nystagmus Diplopia Stained fingernails
Dazed appearance Dizziness or unsteady gait Slurred speech Forgetfulness or difficulty concentrating Anorexia or nausea Irritability or excitability Anxiety Sleep disturbances
Adapted with permission from Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am 1998;25:161.
Because of the variety of solvents that are inhaled, the range of adverse effects is quite broad9 (Table 4).14 Furthermore, it is difficult to pinpoint which chemicals cause adverse effects, because the biologically active compound is often a metabolite of the listed active compound.
TABLE 4 Adverse Effects of Inhalants
Adverse Effects of Inhalants
Hypoxia-induced heart block
Sudden sniffing death syndrome
Nausea or vomiting
Bone marrow suppression
Change in speech
White matter degeneration
Cough or wheezing
Acute renal failure
Renal tubular acidosis
Adapted with permission from Brouette T, Anton R. Clinical review of inhalants. Am J Addict 2001;10:84.
The most serious acute consequence of inhalant abuse is death, which usually occurs secondary to aspiration, accidental trauma, or asphyxia. Other acute causes of death include cardiac arrhythmias, anoxia, vagal inhibition, and respiratory depression. As many as 50 percent of inhalant-related deaths are caused by sudden sniffing death syndrome.15,16 This syndrome occurs when the acutely intoxicated inhalant abuser is startled, causing the release of a burst of catecholamines that can trigger ventricular fibrillation.8 Other serious acute effects include burns from accidental flash fires, hypothermic injuries from propellants, and the triggering of underlying asthma or allergic reactions.
Chronic inhalant use causes toxicity to several organs, including the brain, heart, lung, kidney, liver, and bone marrow. Cardiac toxicity encompasses myocardial edema, irreversible myocarditis, fibrosis, and congestive heart failure.8 Respiratory damage often is related to toluene abuse and can include panacinar emphysema17 and Goodpasture's syndrome.18 Renal toxicity entails distal renal tubular acidosis, anion-gap acidosis, Fanconi's syndrome, renal calculi, hematuria, proteinuria, and renal failure. Toluene-induced renal tubular acidosis is reversible after cessation of inhalants. Long-term inhalant use can result in bone marrow suppression, leading to leukopenia, anemia, thrombocytopenia, and hemolysis.11 Hepatic toxicity also has been reported.19
Neurologic toxicity is the most recognized and reported chronic side effect of inhaled solvent abuse. Common findings on brain imaging include enlarged ventricles, widened cortical sulci, and cerebral, cerebellar, or brain stem atrophy.8 Magnetic resonance imaging suggests that these white-matter changes in chronic abusers are irreversible.20 Dementia, chronic encephalopathy, and peripheral neuropathy also occur. Peripheral neuropathy may present as proximal or distal muscle weakness, muscle wasting, absent or decreased tendon reflexes, or paresthesias. Peripheral neuropathy may be confused with Guillain-Barré syndrome but can be distinguished by sural nerve biopsy, which will show axonal swelling in inhalant abusers.8
Inhalant abuse by women who are pregnant can increase the risks of spontaneous abortion. It also can result in fetal solvent syndrome, which manifests as low birth weight, small head size, facial dysmorphology, and muscle tone abnormalities similar to those occurring in fetal alcohol syndrome.13
The diagnosis of inhalant abuse relies almost entirely on a high index of suspicion. A diligent history and a thorough physical examination are the mainstays of diagnosis.
Only a few laboratory tests are helpful in detecting inhalant abuse. Suggested laboratory testing for a patient presenting with acute inhalant intoxication or suspected inhalant use includes a complete blood count, determination of electrolyte, phosphorous, and calcium levels, an acid-base assessment, hepatic and renal profiles, and cardiac/muscle enzyme analysis.11
Blood collected in a sealed tube containing ethylenediaminetetraacetic acid or heparin can be analyzed by gas chromatography for the presence of aliphatic hydrocarbons (the substances found in inhaled solvents).11 However, this test is usually unavailable on an emergency basis.
A urine drug screen is recommended to rule out other illicit drug use. An electrocardiogram should be obtained to detect dysrhythmias, and brain imaging should be performed if neurologic findings are present.
The treatment of acute inhalation-related injury and illness is generally supportive. Acute dysrhythmias should be treated according to established protocols. The use of sympathomimetics (e.g., epinephrine, norepinephrine, isoproterenol [Isuprel]) should be avoided in patients with ventricular fibrillation.21 Beta blockers should be administered early to protect the catecholamine-sensitized heart. Acid-base and metabolic disturbances should be corrected. Cardiopulmonary monitoring is recommended because of the risk of apnea and cardiac arrest after acute exposure.12
Many acute neurologic findings are reversible after cessation of inhalants. Chronic neurologic sequelae (e.g., dementia, cerebral dysfunction, cerebellar dysfunction) are often permanent and difficult to manage.
Treatment of inhalant abuse and dependence involves counseling, strict abstinence by the abuser, and other drug dependency protocols (e.g., 12-step programs, support groups, inpatient and outpatient dependency treatment). However, a survey22 of drug treatment providers concluded that most treatment programs are not yet adequately equipped to handle inhalant abuse or dependence. While addiction to inhalants has been reported in various case studies, no studies have estimated its prevalence.
Tolerance to inhalants can develop with frequent use. A withdrawal syndrome has been described, although it occurs infrequently. When withdrawal occurs, it should be supported in a controlled setting, if possible. Withdrawal symptoms are similar to those that occur in withdrawal from alcohol or benzodiazepines. Symptoms can include sleep disturbance, irritability, jitteriness, diaphoresis, nausea, vomiting, tachycardia and, occasionally, hallucinations or delusions.5(pp257–60) Withdrawal can last one month or longer, and relapse rates are high.22
Currently, no specific agents can reverse acute solvent intoxication. In addition, no medications have proved helpful in the treatment of inhalant withdrawal or dependence.
Prevention of inhalant abuse is a primary goal, and preadolescents and adolescents should be given extra attention. In addition to questions about tobacco, alcohol, or other drug use, the social history should include a question about “huffing” and “sniffing.” For example, “Have you or your friends ever tried sniffing glue or paint thinner?” Any experimentation by the patient or the patient's friends should be considered a risk factor.
The dangers of sudden death, burns, flash fires, and serious brain damage should be reiterated to patients who are at risk for inhalant abuse. Parents also should be informed about the dangers and warning signs of inhalant abuse. Promoting education of children, parents, and teachers is essential to curtailing inhalant abuse.16 [Evidence level C, expert opinion]
1. 2001 Monitoring the future survey release. Smoking among teenagers decreases sharply and increase in ecstasy use slows. U.S. Department of Health and Human Services HHS News; December 19, 2001. Retrieved July 3, 2003, from: www.nida.nih.gov/MedAdv/01/NR12-19.html.
2. McGarvey EL, Clavet GJ, Mason W, Waite D. Adolescent inhalant abuse: environments of use. Am J Drug Alcohol Abuse. 1999;25:731–41.
3. Bennett ME, Walters ST, Miller JH, Woodall WG. Relationship of early inhalant use to substance use in college students. J Subst Abuse. 2000;12:227–40.
4. Young SJ, Longstaffe S, Tenenbein M. Inhalant abuse and the abuse of other drugs. Am J Drug Alcohol Abuse. 1999;25:371–5.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 2000:239,257–60.
6. Bowen SE, Daniel J, Balster RL. Deaths associated with inhalant abuse in Virginia from 1987 to 1996. Drug Alcohol Depend. 1999;53:239–45.
7. Sharp CW, Rosenberg NL. Inhalants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook. 3d ed. Baltimore: Williams & Wilkins, 1997:246–64.
8. Meadows R, Verghese A. Medical complications of glue sniffing. South Med J. 1996;89:455–62.
9. Balster RL. Neural basis of inhalant abuse. Drug Alcohol Depend. 1998;51:207–14.
10. Fendrich M, Mackesy-Amiti ME, Wislar JS, Goldstein PJ. Childhood abuse and the use of inhalants: differences by degree of use. Am J Public Health. 1997;87:765–9.
11. Broussard LA. The role of the laboratory in detecting inhalant abuse. Clin Lab Sci. 2000;13:205–9.
12. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health. 2001;28:170–80.
13. Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am. 1998;25:153–67.
14. Brouette T, Anton R. Clinical review of inhalants. Am J Addict. 2001;10:79–94.
15. Bass M. Sudden sniffing death. JAMA. 1970;212:2075–9.
16. Inhalant abuse. American Academy of Pediatrics, Committee on Substance Abuse and Committee on Native American Child Health. Pediatrics. 1996;97:420–3.
17. Schikler KN, Lane EE, Seitz K, Collins WM. Solvent abuse associated pulmonary abnormalities. Adv Alcohol Subst Abuse. 1984;3:75–81.
18. Robert R, Touchard G, Meurice JC, Pourrat O, Yver L. Severe Goodpasture's syndrome after glue sniffing. Nephrol Dial Transplant. 1988;3:483–4.
19. O'Brien E, Yeoman WB, Hobby JA. Hepatorenal damage from toluene in a “glue-sniffer.”. Br Med J. 1971;2:29–30.
20. Maruff P, Burns CB, Tyler P, Currie BJ, Currie J. Neurological and cognitive abnormalities associated with chronic petrol sniffing. Brain. 1998;121(pt 10):1903–17.
21. Adgey AA, Johnston PW, McMechan S. Sudden cardiac death and substance abuse. Resuscitation. 1995;29:219–21.
22. Beauvais F, Jumper-Thurman P, Plested B, Helm H. A survey of attitudes among drug user treatment providers toward the treatment of inhalant users. Subst Use Misuse. 2002;37:1391–410.
Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions